Analysts "see value" in $75 cash-plus bid for Genzyme

Analysts figure Sanofi-Aventis could increase the value of its offer for Genzyme to $75 in cash per share, plus $2 to $3 in contingent value rights, Bloomberg reports; the company's current bid expires at the end of the week. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.